About Us Meet the team that is changing how we look at medicine

Stuart Kauffman, MD

Kauffman graduated from Dartmouth in 1960, was awarded the BA (Hons) by Oxford University (where he was a Marshall Scholar) in 1963, and completed a medical degree (M.D.) at the University of California, San Francisco in 1968. After completing his residency in Emergency Medicine, he moved into developmental genetics of the fruitfly, holding appointments first at the University of Chicago, then at the University of Pennsylvania from 1975 to 1995, where he rose to Professor of Biochemistry and Biophysics. Kauffman held a MacArthur Fellowship, 1987–1992.

Kauffman rose to prominence through his association with the Santa Fe Institute (a non­profit research institute dedicated to the study of complex systems), where he was faculty in residence from 1986 to 1997, and through his work on models in various areas of biology. These included autocatalytic sets in origin of life research, gene regulatory networks in developmental biology, and fitness landscapes in evolutionary biology. Kauffman holds the founding broad biotechnology patents in combinatorial chemistry and applied molecular evolution.

In 1996, Kauffman started BiosGroup, a Santa Fe, New Mexico based for-­profit company that applied complex systems methodology to business problems. BiosGroup was acquired by NuTech Solutions in early 2003. NuTech was bought by Netezza in 2008.

From 2004 to 2009 Kauffman held a joint appointment at the University of Calgary in Biological Sciences and Physics and Astronomy. He is also an Adjunct Professor in the Department of Philosophy at the University of Calgary. He is an iCORE (Informatics Research Circle of Excellence) chair and the director of the Institute for Biocomplexity and Informatics.

In January 2009 Kauffman became a Finland Distinguished Professor (FiDiPro) at Tampere University of Technology, Department of Signal Processing. The appointment is until the end of 2012. The subject of the FiDiPro research project is the development of delayed stochastic models of genetic regulatory networks based on gene expression data at the single molecule level.

In January 2010 Kauffman joined the University of Vermont faculty where he will continue his work with UVM's Complex Systems Center. He is also an adviser to the Microbes Mind Forum.

Kauffman is a MacArthur Fellow and a Trotter Prize winner, Kauffman has published four major books, among them is At Home in the Universe: The Search for the Laws of Self­ Organization and Complexity (1995).

Stuart Kauffman is currently working at Institute of Systems Biology.

Leroy Hood, MD, PhD

Dr. Leroy Hood is a world­ renowned scientist, inventor, entrepreneur and visionary. His discoveries have permanently changed the course of biology, and revolutionized the understanding of genetics, life, and human health. The inventions developed under his leadership include the automated DNA sequencer and an automated tool for synthesizing DNA. He opened the door to the era of big data in medicine.

Hood created the technological foundation for the sciences of genomics (study of genes) and proteomics (study of proteins) through the invention of five groundbreaking instruments and by explicating the potentialities of genome and proteome research into the future through his pioneering of the fields of systems biology and systems medicine. Hood's instruments not only pioneered the deciphering of biological information, but also introduced the concept of high throughput data accumulation through automation and parallelization of the protein and DNA chemistries.

Hood is one of only 15 members of all three United States National Academies, the National Academy of Engineering, the National Academy of Sciences, and the Institute of Medicine. Lee Hood serves as Chairman of the P4 Medicine Institute and as President of the Institute for Systems Biology.

Colin Hill

Colin Hill co-founded GNS Healthcare in 2000 and has served as CEO since then. He brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics, artificial intelligence, and personalized medicine. He serves as Chairman of Via Science, a leading big data analytics company focused on the Internet of Things, business intelligence, and finance . He was also a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatment for sickle cell disease (acquired by Baxter in 2014). Colin was the founding chairman of O'Reilly Media's Strata Rx, the first healthcare big data conference.

In 2004, Colin was named to MIT Technology Review's TR100 list of the top innovators in the world under the age of 35. He is a frequent speaker at national and international scientific and industry conferences and has been quoted in in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned masters degrees in physics from both McGill University and Cornell University.

Kathleen O'Connell

Kathleen O'Connell is an Edward R. Murrow, Peabody, Alfred I. Dupont and Emmy award winning network television news producer specializing in social issues and content development. She is an experienced long­form documentary and newsmagazine producer. Kathleen coordinated and developed visual content for A World Free From Cancer initiative and Value of Medical Innovation. Kathleen is a leading advocate for families navigating the complicated and often perilous journey of a terminally ill diagnosis of a child. She counsels families with brain cancer diagnosis for Imerman Angels, executive produced 35th anniversary film for Friends of Karen, a non profit cancer advocacy organization. Kathleen lives in Sleepy Hollow, NY, and is the mother of 2 children.

Her 14 ­year ­old son, Lucas, died in 2010 from a rare, inoperable, brain tumor. Her interaction with the health care system inspired her to advocate for faster access to experimental drugs for terminally ill patients.

Lucas remembered:
The Power Of Mother Love

Robert Goldberg, PhD

Robert Goldberg is Vice President and co­founder of the Center for Medicine in the Public Interest, a non­profit organization that advocates for consumer access to medical innovation, better health information and personalized healthcare. He is also the founder of CMPI's Value of Medical Innovation initiative, which promotes awareness of the value of medical progress, and co­founder of My Life is Worth It iniative, an online patient­led campaign against practices and policies that deny access to new medicines based on cost.

Dr. Goldberg is also an advisor to several biotech start ups including Myos Corporation, Nanobiosystems, and Human Longevity, Inc. Prior to founding CMPI, Goldberg was Director of the Manhattan Institute's Center for Medical Progress and Chairman of its 21st Century FDA Task Force, which examined the impact of the FDA's Critical Path Initiative on drug development and personalized medicine.

Hans Kaspersetz

Hans Kaspersetz is the founder and president of Arteric, a healthcare marketing agency built on a foundation of state-of-the-art software engineering. A lifelong software developer, Hans builds and guides teams of world-class software developers that drive change in healthcare and other industries. Through the decades, Hans evangelized many of the precursor technologies to today’s web standards and led the adoption of contemporary technologies such as PHP, Apache, Linux, and open source in healthcare. A speaker and panelist at international technology meetings, Hans advises Fortune Global 500 firms on commercial web search technology and digital strategy.

Hans is a relentless explorer who lives to push boundaries, make discoveries and share what he learns. His passion for technology and desire to help people live longer, healthier lives fuel his efforts to connect the public and healthcare professionals with information about life-changing therapies, technologies and devices. Hans envisions a future where healthcare, daily life and technology are indistinguishable. He's thrilled to help Transforming Medicine develop the systems that accelerate the adoption of personalized medicine.

Ilya Shmulevich, PhD

Dr. Shmulevich joined the Institute for Systems Biology faculty 2005 where he is currently a Professor. He directs a Genome Data Analysis Center as part of The Cancer Genome Atlas (TCGA) project, a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large­scale genome sequencing. He also directs the Computational Core of the Systems Approach to Immunity and Inflammation consortium, which consists of a large multidisciplinary team of investigators working in the fields of immunology and systems biology. These projects entail the development of computational and mathematical approaches for modeling biological systems and analyzing large­scale measurement data sets. Dr. Shmulevich's research interests also include theoretical studies of complex systems, including information theoretic approaches, as well as the application of image processing and analysis to high­throughput cellular imaging.

Dr. Shmulevich is a co­editor or co­author of six books in the areas of computational biology.

Sui Huang, MD, PhD

Dr. Huang joined Institute for Systems Biology in the summer of 2011 from the University of Calgary. Huang Group is interested in the fundamental principles that govern how the gene regulatory network (GRN) orchestrate the activities of the genes to produce the variety of stable cellular states, such as the known cell types of the body, which in turn undergo state transitions, such as the differentiation of a multi­potent stem cell to a specialized blood cell. The theoretical framework that guides research in the laboratory is that these stable cell states are "attractors" in the rugged epigenetic landscape that epitomizes the global non­linear dynamics of the gene regulatory network.

Nicholas Schork, PhD

Nicholas J. Schork is a Professor and Director of Human Biology at the J. Craig Venter Institute (JCVI). He is also an adjunct Professor of Psychiatry and Family and Preventive Medicine (Division of Biostatistics) at the University of California, San Diego (UCSD). Prior to joining JCVI, Dr. Schork was, from 2007­-2013, a Professor, Molecular and Experimental Medicine, at The Scripps Research Institute (TSRI), Director of Biostatistics and Bioinformatics at the Scripps Translational Science Institute (STSI), and Director of Research at Scripps Genomic Medicine, a division of Scripps Health.

Dr. Schork's interests and expertise are in quantitative human genetics and integrated approaches to complex biological and medical problems, especially the design and implementation of methodologies to dissect the determinants of complex traits and diseases. ­

Robert Hariri MD, PhD

As the founder and chief executive officer of Celgene Cellular Therapeutics, Dr. Hariri pioneered the use of human stem cells to treat a range of life­threatening diseases. In his career as an academic neurosurgeon and trauma specialist at Cornell University, biotechnology executive, military surgeon and aviator, and serial entrepreneur, he is most recognized for his discovery of pluripotent stem cells from placenta and as a member of the team that discovered tumor necrosis factor. Dr. Hariri was awarded the Thomas Alva Edison Award in 2007 for his discovery of placental stem cells and again in 2011 for engineering tissues and organs from stem cells. He has authored over 100 scientific articles and chapters and has over 80 issued and pending patents.

Dr. Hariri serves on numerous boards including Human Longevity Inc., MYOS Corporation and Provista Diagnostics, is a member of the Board of Visitors of The Fu Foundation School of Engineering and Applied Science and the Science and Technology Council of the Columbia University College of Physicians and Surgeons, is a Trustee of the Liberty Science Center.

Howard Fine, MD

Dr. Howard Fine is the Director of the newly established Brain Tumor Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Additionally, he is the Associate Director for translational research in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College, as well as Chief of the Division of Neuro-Oncology in the Department of Neurology at NewYork-Presbyterian/Weill Cornell.

Prior to joining NewYork-Presbyterian/Weill Cornell, he built two of the nation's leading neuro-oncology programs, the Dana-Farber Cancer Institute Center for Neuro-Oncology at Harvard Medical School and the Neuro-Oncology Branch at the National Institutes of Health; programs known for offering state-of-the-art research and clinical programs that provided cutting-edge treatments for patients with brain tumors. He has run a basic and translational genetic and molecular science laboratory throughout his 26-year career, and has been involved in more than 100 brain tumor clinical trials.

Dr. Fine received his medical degree at the Mount Sinai School of Medicine in New York City. He completed an internship and residency in Internal Medicine at the Perelman School of Medicine at the University of Pennsylvania, followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. Most recently, Dr. Fine served as Deputy Director of the Cancer Center, Chief of the Division of hematology and Oncology and Director of the Brain Tumor Center at New York University Langone Medical Center.

Dr. Fine has authored more than 200 scholarly articles, reviews and book chapters in subjects related to neuro-oncology and brain tumors, and served on the editorial boards of Neuro-Oncology and The Journal of Clinical Oncology. His numerous awards and honors include the Community Leadership Award for Service from the National Brain Tumor Society, The National Service to America Award and the National Cancer Institute Director's Gold Star Award for vision, leadership and advice in designing cancer programs for the future using neuro-oncology as a model.

Henry Friedman, MD

Dr. Henry S. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings.

Dr. Friedman has proven experience in drug development working with leaders in the pharmaceutical industry, Food and Drug Administration, National Cancer Institute and advocacy groups. He is a seasoned innovator and team builder who has built organization cultures for new products and therapy development. He is an expert connector with a network of decision makers in a broad spectrum of industries including financial/banking, healthcare, health insurance, sports media, federal, legal and political.

Dr. Friedman is a committed educator who is a member of the Executive and Super Executive Committees of Duke Medical School which is responsible for the recruitment, screening and selection of medical students. He has reviewed grants for the National Institutes of Health for over 15 years in a spectrum of different study sections. He is the senior editor of CNS Oncology, the Associate Editor for the Neuro-Oncology Section of Cancer and is a reviewer for over 25 academic journals.

Dr. Friedman serves on the advisory board of a number of organizations including Voices Against Brain Cancer, the Tug McGraw Foundation, Pinnacle Care, the Pediatric Brain Tumor Foundation, the National Children's Cancer Society and the Association for Brain Tumor Research. He is on the Executive Board of TEAM Doctors Preferred Access. He has received a number of awards for his work including the Visionary Award from the Tug McGraw Foundation, the Gary Lichtenstein Humanitarian Award from the Voices Against Brain Cancer Foundation and the Healthnetwork Foundation Service Excellence Award. He is a member of the American Society of Clinical Investigation.

Walter Capone

Mr. Walter M. Capone, M.B.A, serves as the Chief Financial Officer and Vice President of Commercial of Intelligent Therapeutic Solutions Inc. He is Senior Advisor at 2020 HealthCare Partners LLC. Mr. Capone served as the Chief Executive Officer and President of The Multiple Myeloma Research Foundation, Inc since June 30, 2014 and served as its Chief Operating Officer since December 16, 2013. From 2010-2016, he was Chief Executive Officer & President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), where he transformed the Foundation to leverage industry experience, academic research and FDA collaborations. He served as Vice President of Commercial Development and Operations of Progenics Pharmaceuticals Inc. since January 8, 2007. Mr. Capone served as Senior Vice President of Commercial Operations for Trimeris, Inc. from 2002 to 2007, where he managed the FUZEON® and fusion inhibitor commercial collaboration with Hoffmann LaRoche. He served as Vice President of Marketing & Development for Triangle Pharmaceuticals, Inc., where he led the commercial development of HIV (human immunodeficiency virus), hepatitis B and cancer drug candidates. In his roles as SVP Commercial Operations, VP Commercial Development, and Division Manager for Progenics, Triangle Pharmaceuticals, Trimeris, BMS, Wyeth and Lederle, Walter has led the development and launch of over 18 novel drugs. Mr. Capone served as Director of Infectious Diseases and Immunology for Bristol Myers-Squibb, managing their portfolio of Antimicrobial, Antiviral, and Immunological drugs in international markets. He served as Chief Financial Officer and Member of the Board of Directors of Intelligent Therapeutic Solutions Inc. Mr. Capone has 19 years of U.S. and international commercial leadership experience within the pharmaceutical and biotechnology industries. He served in marketing and sales management positions in the U.S. and The Netherlands for Lederle Pharmaceuticals, now part of Wyeth, Inc. He held successive senior management positions in marketing, sales and business development at Bristol-Myers Squibb, American Home Products Co. and the Lederle Pharmaceuticals Division of American Cyanamid. He is an accomplished, global Biotech/Pharma leader with a twenty year track record of accelerating breakthrough science, drug development and commercialization. His therapeutic experience spans the immunology, oncology and infectious disease areas. Mr. Capone earned his MBA in Finance and International Business from Columbia University School of Business, and an B.A. in International Relations from Brown University in Providence, Rhode Island.

Michael Klipper

Michael Klipper, a formulary chemist, entrepreneur, author, and fundraiser is Director of Business Development for Transforming Medicine. He is a Founding Board Member of Voices Against Brain Cancer (VABC), a 501(c)(3) committed to finding a cure for brain cancer and brain tumors by advancing scientific research and supporting patients, their families and caregivers afflicted with this devastating disease. Since it's inception, Michael has held an active role on VABC's Granting Committee and has forged relationships with the leading neuro oncologists, surgeons, and researchers. In 2009, his role expanded to that of Chairman of VABC where under his leadership, millions have been raised to fund scientific research and support programs for the brain cancer community. Michael continues to champion pioneering efforts in brain cancer treatments.

Prior to joining TMED, Michael was President & CEO of The Klipper Group, 1996-2013, a family of companies actively involved in formulary chemistry, developing chemical compounds, processes, and metering delivery devices. He is the co-author of Textile Laundering Technology, a publication recognized as the "bible" for the textile process industry. Former Director, 2010 - 2014, DC NetCast Media Group where his role as Business Strategist has led to the formation of several successful publicly and privately held companies.

Michael owns a professional recording studio, and enjoys writing, producing, and performing music. He is a Graduate of Farleigh Dickenson University.

GNS Healthcare

GNS Healthcare is a big data analytics company that empowers payers, providers and pharmaceutical companies to make intelligent data ­driven decisions. We unlock knowledge within complex data, enabling personalized, actionable predictions and precision targeting. For 15 years, GNS has been committed to developing and deploying the most sophisticated mathematical and computational platforms to help our partners improve health and reduce costs.

Institute for Systems Biology

The Institute for Systems Biology is a nonprofit biomedical research organization based in Seattle, Washington. It was founded in 2000 by systems biologist Leroy Hood, immunologist Alan Aderem, and protein chemist Ruedi Aebersold. ISB was established on the belief that the conventional models for exploring and funding breakthrough science have not caught up with the real potential of what is possible today.

  • Patty Gillette and Steve Norman
  • The O'Connell Family (in honor of Lucas Goldbaum)
  • Dr. Joseph and Suzanne O'Connell
  • Katherine Peil
  • Kenneth and Evelyn Polcari
  • Angelica and Michael Cammarota
  • Charlene Jue
  • Elvira Aloia
  • Marnie and Peter Gelfman
  • Norm Parton and Ellie Becker
  • Evan Walker
  • Elisa Shannon
  • Stephen R. Seiler